Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients

Enric Carcereny, Jose Luis Ramirez, Maria Sanchez-Ronco, Dolores Isla, Manuel Cobo, Teresa Moran, Itziar de Aguirre, Tatsuro Okamoto, Jia Wei, Mariano Provencio, Guillermo Lopez-Vivanco, Carlos Camps, Manuel Domine, Vicente Alberola, Jose Miguel Sanchez, Bartomeu Massuti, Pedro Mendez, Miquel Taron, Rafael Rosell

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Nicotine acetylcholine receptors (nAChRs) are associated with resistance to gemcitabine, cisplatin and paclitaxel in non-small-cell lung cancer (NSCLC) cell lines. Three single nucleotide polymorphisms (SNPs) of CHRNA3, CHRNA5 and LOC123688 increase lung cancer risk. These SNPs may have influenced outcome in patients treated in our phase III trial. Stage IV NSCLC patients were treated with customized chemotherapy based on ERCC1 (excision repair cross-complementing 1) mRNA expression. Patients in the control arm received docetaxel/cisplatin; patients in the genotypic arm with low levels of ERCC1 received docetaxel/cisplatin; patients in the genotypic arm with high levels of ERCC1 received docetaxel/gemcitabine. DNA was extracted from lymphocytes, and CHRNA3 (rs1051730), CHRNA5 (rs16969968) and LOC123688 (rs8034191) SNPs were genotyped with the Taqman allele discrimination assay. A significant interaction was found for CHRNA3 and PS (P= 0.02). In patients with PS 0, CT patients had a better response than both CC (P= 0.01) and TT (P= 0.02) patients, and patients in the low genotypic group also had a better response (P= 0.01). When the CHRNA3 genotype was added in the multivariate analysis for progression-free survival, an improvement was observed in the low genotypic group in PS 0 patients (P= 0.02). PS 0 patients in the low genotypic group with the CT genotype attained an 84% response rate, 12.1-month progression-free survival, and 19-month median survival. CHRNA3 (rs1051730) genotyping can improve customized chemotherapy based on tumor assessment of ERCC1 mRNA in stage IV NSCLC with PS 0.

Original languageEnglish
Pages (from-to)491-497
Number of pages7
JournalLung Cancer
Volume68
Issue number3
DOIs
Publication statusPublished - Jun 1 2010

Fingerprint

Non-Small Cell Lung Carcinoma
Single Nucleotide Polymorphism
docetaxel
gemcitabine
DNA Repair
Cisplatin
Disease-Free Survival
Genotype
Drug Therapy
Messenger RNA
Cholinergic Receptors
Nicotine
Lung Neoplasms
Multivariate Analysis
Alleles
Lymphocytes
Cell Line
Survival
DNA

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Carcereny, E., Ramirez, J. L., Sanchez-Ronco, M., Isla, D., Cobo, M., Moran, T., ... Rosell, R. (2010). Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients. Lung Cancer, 68(3), 491-497. https://doi.org/10.1016/j.lungcan.2009.08.004

Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients. / Carcereny, Enric; Ramirez, Jose Luis; Sanchez-Ronco, Maria; Isla, Dolores; Cobo, Manuel; Moran, Teresa; de Aguirre, Itziar; Okamoto, Tatsuro; Wei, Jia; Provencio, Mariano; Lopez-Vivanco, Guillermo; Camps, Carlos; Domine, Manuel; Alberola, Vicente; Sanchez, Jose Miguel; Massuti, Bartomeu; Mendez, Pedro; Taron, Miquel; Rosell, Rafael.

In: Lung Cancer, Vol. 68, No. 3, 01.06.2010, p. 491-497.

Research output: Contribution to journalArticle

Carcereny, E, Ramirez, JL, Sanchez-Ronco, M, Isla, D, Cobo, M, Moran, T, de Aguirre, I, Okamoto, T, Wei, J, Provencio, M, Lopez-Vivanco, G, Camps, C, Domine, M, Alberola, V, Sanchez, JM, Massuti, B, Mendez, P, Taron, M & Rosell, R 2010, 'Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients', Lung Cancer, vol. 68, no. 3, pp. 491-497. https://doi.org/10.1016/j.lungcan.2009.08.004
Carcereny, Enric ; Ramirez, Jose Luis ; Sanchez-Ronco, Maria ; Isla, Dolores ; Cobo, Manuel ; Moran, Teresa ; de Aguirre, Itziar ; Okamoto, Tatsuro ; Wei, Jia ; Provencio, Mariano ; Lopez-Vivanco, Guillermo ; Camps, Carlos ; Domine, Manuel ; Alberola, Vicente ; Sanchez, Jose Miguel ; Massuti, Bartomeu ; Mendez, Pedro ; Taron, Miquel ; Rosell, Rafael. / Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients. In: Lung Cancer. 2010 ; Vol. 68, No. 3. pp. 491-497.
@article{47a7d8cd45d44c8685bab4a94a660d54,
title = "Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients",
abstract = "Nicotine acetylcholine receptors (nAChRs) are associated with resistance to gemcitabine, cisplatin and paclitaxel in non-small-cell lung cancer (NSCLC) cell lines. Three single nucleotide polymorphisms (SNPs) of CHRNA3, CHRNA5 and LOC123688 increase lung cancer risk. These SNPs may have influenced outcome in patients treated in our phase III trial. Stage IV NSCLC patients were treated with customized chemotherapy based on ERCC1 (excision repair cross-complementing 1) mRNA expression. Patients in the control arm received docetaxel/cisplatin; patients in the genotypic arm with low levels of ERCC1 received docetaxel/cisplatin; patients in the genotypic arm with high levels of ERCC1 received docetaxel/gemcitabine. DNA was extracted from lymphocytes, and CHRNA3 (rs1051730), CHRNA5 (rs16969968) and LOC123688 (rs8034191) SNPs were genotyped with the Taqman allele discrimination assay. A significant interaction was found for CHRNA3 and PS (P= 0.02). In patients with PS 0, CT patients had a better response than both CC (P= 0.01) and TT (P= 0.02) patients, and patients in the low genotypic group also had a better response (P= 0.01). When the CHRNA3 genotype was added in the multivariate analysis for progression-free survival, an improvement was observed in the low genotypic group in PS 0 patients (P= 0.02). PS 0 patients in the low genotypic group with the CT genotype attained an 84{\%} response rate, 12.1-month progression-free survival, and 19-month median survival. CHRNA3 (rs1051730) genotyping can improve customized chemotherapy based on tumor assessment of ERCC1 mRNA in stage IV NSCLC with PS 0.",
author = "Enric Carcereny and Ramirez, {Jose Luis} and Maria Sanchez-Ronco and Dolores Isla and Manuel Cobo and Teresa Moran and {de Aguirre}, Itziar and Tatsuro Okamoto and Jia Wei and Mariano Provencio and Guillermo Lopez-Vivanco and Carlos Camps and Manuel Domine and Vicente Alberola and Sanchez, {Jose Miguel} and Bartomeu Massuti and Pedro Mendez and Miquel Taron and Rafael Rosell",
year = "2010",
month = "6",
day = "1",
doi = "10.1016/j.lungcan.2009.08.004",
language = "English",
volume = "68",
pages = "491--497",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients

AU - Carcereny, Enric

AU - Ramirez, Jose Luis

AU - Sanchez-Ronco, Maria

AU - Isla, Dolores

AU - Cobo, Manuel

AU - Moran, Teresa

AU - de Aguirre, Itziar

AU - Okamoto, Tatsuro

AU - Wei, Jia

AU - Provencio, Mariano

AU - Lopez-Vivanco, Guillermo

AU - Camps, Carlos

AU - Domine, Manuel

AU - Alberola, Vicente

AU - Sanchez, Jose Miguel

AU - Massuti, Bartomeu

AU - Mendez, Pedro

AU - Taron, Miquel

AU - Rosell, Rafael

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Nicotine acetylcholine receptors (nAChRs) are associated with resistance to gemcitabine, cisplatin and paclitaxel in non-small-cell lung cancer (NSCLC) cell lines. Three single nucleotide polymorphisms (SNPs) of CHRNA3, CHRNA5 and LOC123688 increase lung cancer risk. These SNPs may have influenced outcome in patients treated in our phase III trial. Stage IV NSCLC patients were treated with customized chemotherapy based on ERCC1 (excision repair cross-complementing 1) mRNA expression. Patients in the control arm received docetaxel/cisplatin; patients in the genotypic arm with low levels of ERCC1 received docetaxel/cisplatin; patients in the genotypic arm with high levels of ERCC1 received docetaxel/gemcitabine. DNA was extracted from lymphocytes, and CHRNA3 (rs1051730), CHRNA5 (rs16969968) and LOC123688 (rs8034191) SNPs were genotyped with the Taqman allele discrimination assay. A significant interaction was found for CHRNA3 and PS (P= 0.02). In patients with PS 0, CT patients had a better response than both CC (P= 0.01) and TT (P= 0.02) patients, and patients in the low genotypic group also had a better response (P= 0.01). When the CHRNA3 genotype was added in the multivariate analysis for progression-free survival, an improvement was observed in the low genotypic group in PS 0 patients (P= 0.02). PS 0 patients in the low genotypic group with the CT genotype attained an 84% response rate, 12.1-month progression-free survival, and 19-month median survival. CHRNA3 (rs1051730) genotyping can improve customized chemotherapy based on tumor assessment of ERCC1 mRNA in stage IV NSCLC with PS 0.

AB - Nicotine acetylcholine receptors (nAChRs) are associated with resistance to gemcitabine, cisplatin and paclitaxel in non-small-cell lung cancer (NSCLC) cell lines. Three single nucleotide polymorphisms (SNPs) of CHRNA3, CHRNA5 and LOC123688 increase lung cancer risk. These SNPs may have influenced outcome in patients treated in our phase III trial. Stage IV NSCLC patients were treated with customized chemotherapy based on ERCC1 (excision repair cross-complementing 1) mRNA expression. Patients in the control arm received docetaxel/cisplatin; patients in the genotypic arm with low levels of ERCC1 received docetaxel/cisplatin; patients in the genotypic arm with high levels of ERCC1 received docetaxel/gemcitabine. DNA was extracted from lymphocytes, and CHRNA3 (rs1051730), CHRNA5 (rs16969968) and LOC123688 (rs8034191) SNPs were genotyped with the Taqman allele discrimination assay. A significant interaction was found for CHRNA3 and PS (P= 0.02). In patients with PS 0, CT patients had a better response than both CC (P= 0.01) and TT (P= 0.02) patients, and patients in the low genotypic group also had a better response (P= 0.01). When the CHRNA3 genotype was added in the multivariate analysis for progression-free survival, an improvement was observed in the low genotypic group in PS 0 patients (P= 0.02). PS 0 patients in the low genotypic group with the CT genotype attained an 84% response rate, 12.1-month progression-free survival, and 19-month median survival. CHRNA3 (rs1051730) genotyping can improve customized chemotherapy based on tumor assessment of ERCC1 mRNA in stage IV NSCLC with PS 0.

UR - http://www.scopus.com/inward/record.url?scp=77952553157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952553157&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2009.08.004

DO - 10.1016/j.lungcan.2009.08.004

M3 - Article

C2 - 19733931

AN - SCOPUS:77952553157

VL - 68

SP - 491

EP - 497

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -